Democratisation Of Medicines Policy / Projects

3rd Health Programme (2014-2020)
A Plan for Action: Ensuring Equitable, Affordable and Responsibly Used Medicines in the European Union [HAI_SGA2018]
Health Action International (HAI)'s European 2018 work plan builds on previous work supported by CHAFEA and aims to provide a response to persistent shortfalls in European medicines policy and regulat...
Health Action International (HAI)'s European 2018 work plan builds on previous work supported by CHAFEA and aims to provide a response to persistent shortfalls in European medicines policy and regulation. HAI’s work plan is aligned with the objectives of the Third Health Programme and with HAI’s organisational goals: (1) Access to Affordable Medicines, (2) Medicines Safety, Added Therapeutic Value and Responsible Use, (3) Democratisation of Medicines Policy.

HAI will keep on addressing those factors affecting access to medicines, including Intellectual Property rights while campaigning to broaden public and policy support to alternative models of biomedical innovation that contribute to medicines affordability and ensure public return on public investment. Advice and support will be provided to measures enhancing generic competition while bolstering governments position in procurement and medicines price negotiations.
As a member of the HTA Network Stakeholders Pool, HAI will contribute to the work of the network and issue recommendations to ensure that collaborative efforts strengthen the quality and robustness of HTA systems in Europe with the ultimate goal to enhance the sustainability of healthcare systems. Regarding the little (or non-existing) added therapeutic value of many new medicines, HAI will seek policy and regulatory support for more robust frameworks for medicines market approval; this will include initiatives for more proactive and robust pharmacovigilance systems to further protect patients’ safety. As a member of the European Medicines Agency (EMA) Patients’ and Consumers’ Working Party (PCWP), HAI will bring an independent consumers’ voice to EMA’s discussions and public consultations. We will closely follow developments in public access to clinical data in the EU and issue recommendations for enhanced transparency. In addition, we will implement initiatives to promote rational use of medicines by healthcare professionals.
Start date: 01/01/2018 - End date: 31/12/2018

Call: Financial contribution to the functioning of non-governmental bodies (Operating grants)
Topic: Democratisation Of Medicines Policy
3rd Health Programme (2014-2020)
A Plan for Action: Ensuring Equitable, Affordable and Responsibly Used Medicines in the European Union [HAI_FPA2018]
Stichting (Foundation) Health Action International's European multi-annual programme 2018-2021 builds on previous work supported by CHAFEA and aims to provide a response to persistent shortfalls in Eu...
Stichting (Foundation) Health Action International's European multi-annual programme 2018-2021 builds on previous work supported by CHAFEA and aims to provide a response to persistent shortfalls in European medicines policy. HAI’s work plan is aligned with the objectives of the Third Health Programme and with HAI’s organisational goals: (1) Access to Affordable Medicines, (2) Medicines Safety, Added Therapeutic Value and Responsible Use, (3) Democratisation of Medicines Policy.

In particular, HAI will campaign to broaden public and policy support to alternative models of biomedical innovation that contribute to medicines affordability and ensure public return on public investment. We will also provide advice and support initiatives that enhance generic competition and empower governments in medicines price negotiations. As a member of the HTA Network Stakeholders Pool for the mandate 2016-2020, HAI will contribute to the work of Stakeholders Pool and issue recommendations to ensure that collaborative efforts strengthen the quality and robustness HTA systems in Europe with the ultimate goal to enhance the sustainability of healthcare systems and medical innovation. Following concerns about the little (or non-existing) added therapeutic value of many new medicines, HAI will seek policy and regulatory support for more robust frameworks for medicines. We will support initiatives for more proactive and robust pharmacovigilance systems to further protect patients’ safety. As a member of the European Medicines Agency (EMA) Patients’ and Consumers’ Working Party (PCWP), HAI will bring independent consumers’ voice to EMA’s policies and initiatives. We will follow closely developments on public access to clinical data in the EU and issue recommendations for enhanced transparency. In addition, we will implement initiatives for enhanced rational use of medicines for example by capacitating healthcare professionals to better assess information on medicines.
Start date: 09/03/2018 - End date: 08/03/2022

Call: Operating grants 2018-2021
Topic: Democratisation Of Medicines Policy